Patient-reported outcomes of serum eye drops manufactured from Australian blood donations and packaged using Meise vials

Frontiers in Medicine

Medicine

Carley N. Gemelli¹  Elizabeth Knight¹  Athina Kakkos¹  Justine O’Donovan²  Phillip Mondy²  Perfecto Diaz²  Rena Hirani³ 

[1] Australian Red Cross Lifeblood, Melbourne, VIC, Australia;Australian Red Cross Lifeblood, Sydney, NSW, Australia;Australian Red Cross Lifeblood, Sydney, NSW, Australia;Faculty of Science and Engineering, Macquarie University, Sydney, NSW, Australia;

关键词: blood donation;    serum eye drops;    transfusion medicine;    dry eye;    blood;   

DOI  :  10.3389/fmed.2023.1252688

 received in 2023-07-04, accepted in 2023-08-17,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionSerum eye drops (SED) are an effective treatment for dry eye syndrome. However, autologous serum collection can have challenges. Patient-tailored (allogeneic) SED (PT-SED) can be made from healthy blood donors. Australian Red Cross Lifeblood has manufactured both autologous SED (Auto-SED) and PT-SED and, in May 2021, introduced Meise vial packaging. This study aimed to explore SED patient-reported outcomes and vial packaging satisfaction.MethodsA prospective cohort study was conducted with recruitment between 1 November 2021 and 30 June 2022. Participants completed the dry eye questionnaire (DEQ5), health-related quality-of-life (SF-8™), functional assessment of chronic illness therapy-treatment satisfaction-general (FACIT-TS-G), and general wellbeing surveys. Existing patients completed these once, and new patients were surveyed at baseline, 3 months post-treatment, and 6 months post-treatment.ResultsParticipants who completed all study requirements were 24 existing and 40 new Auto-SED and 10 existing and 8 new PT-SED patients. Auto-SED patients were younger [56.2 (±14.7) years] than PT-SED patients [71.4 (±10.0) years]. Participants used a mean of 1.8 (±1.1) SED, 5.3 (±2.9) times per day. In new patients, DEQ5 scores improved within 6 months from 14.0 (±2.9) to 10.6 (±3.4) for Auto-SED and from 12.9 (±3.7) to 11.4 (±2.8) for PT-SED. General wellbeing measures improved in the new Auto-SED from 7.0 (±1.9) to 7.8 (±1.7) but were reduced for new PT-SED from 6.7 (±2.9) to 6.1 (±2.9).DiscussionSED improved dry eye symptoms in most patients, regardless of the serum source. Patients using PT-SED showed decreases in some quality-of-life measures; however, recruitment was reduced due to operational constraints, and concurrent comorbidities were not assessed. General feedback for SED and vial packaging was positive, with some improvements identified.

【 授权许可】

Unknown   
Copyright © 2023 Gemelli, Mondy, Kakkos, O’Donovan, Diaz, Knight and Hirani.